Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion.Second, a sector rotation may be ...

akinbostanciCentessa Pharmaceuticals (NASDAQ:CNTA) has become an interesting player in the biopharmaceutical field, characterized by an innovative business model and a unique portfolio. Unlike other companies, the unique structure of Centessa combines the flexibility of innovation of small-scale biotechs and the robust support of a large corporation that can give it an advantage in the turbulent world of drug development. Such a framework enables the company to concentrate on the development of its pipe ...

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom (Address of principal executive offices and zip code) +44 7391 789784 Registrant's telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: | --- | --- | --- | |------ ...

The Company's unaudited interim consolidated financial statements include the accounts of Centessa Pharmaceuticals plc, and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Emerging Growth Company and Smaller Reporting Company We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act ("JOBS Act") enacted in April 2012. For so long as we remain an emerging growth company, we are permitted and intend to rely on ce ...

Table of Contents (Exact name of registrant as specified in its charter) England and Wales 98-1612294 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-04321 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98-1612294 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3rd Floor 1 Ashley Road Altrin ...

| --- | --- | --- | |-------------------------------------------------------|-------|-------| | | | | | | | | | Corporate Overview Asset-Centric. Patient-Centric. | | | | | | | | | | | Disclaimer This presentation has been prepared by Centessa Pharmaceuticals plc (the "Company") for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recomme ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-04321 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wale ...

| --- | --- | --- | |-----------------------------------|-------|-------| | | | | | | | | | | | | | Corporate Overview | | | | Asset-Centric. Patient-Centric. | | | Disclaimer This presentation has been prepared by Centessa Pharmaceuticals plc (the "Company") for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors ...

Corporate Overview AUGUST 2022 Disclaimer This presentation has been prepared by Centessa Pharmaceuticals plc (the "Company") for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing or selling of securities or other financial instruments and does not tak ...